PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients

The better understanding of interactions between tumor and immune system (e.g., tumor-associated upregulation of PD-L1 to induce checkpoint for cytotoxic lymphocytes; Figure 1A) gave rise to the development of immune modulating therapies.